Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit
SAN FRANCISCO, Oct. 8, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit. Investors who purchased or acquired Aardvark common stock...
Covered in this story
What has happened since
- Aardvark Therapeutics Inc is down 17.2% since this was published, 12 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $AARD yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Aardvark Therapeutics Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.